Proven smoking cessation treatment, Cytisine (also known as cytisinicline), has been classified among the “more likely” interventions to result in successful quitting for UK smokers in the latest version of The National Institute for Health and Care Excellence (NICE) tobacco guidelines (NG209).(1)
NICE’s update mandates that local commissioners and providers of healthcare in England make Cytisine (cytisinicline) available as a treatment option alongside other established smoking cessation therapies, giving frontline healthcare professionals an additional treatment option in the fight against the ongoing smoking-related health crisis.(1)
“Cytisine is a real game-changer for smoking cessation,” said Beverley Bostock, Advanced Nurse Practitioner, Mann Cottage Surgery, Gloucestershire. “Cytisine offers a short treatment duration compared to many other available treatments, and has a proven track record, making it a practical and effective option. With NICE’s updated guidelines in place, clinicians will freely be able to provide this treatment option, where appropriate, to support more individuals in breaking free from smoking.”
The update to the NICE tobacco guidelines was instigated by the UK launch of Cytisine in January 2024 and included a review of the clinical and cost-effectiveness evidence, which confirmed Cytisine’s position as a first line treatment option for smoking cessation.(1)
“We can now add Cytisine to the list of treatments that, when combined with support from a trained professional, can help individuals to be smoke-free,” said Professor Matthew Evison, Consultant Chest Physician at Wythenshawe Hospital. “Cytisine has a treatment duration of just 25 days and can be administered with a single prescription, meaning no need for repeat prescriptions or appointments for more tablets. Having more treatment options available, and making it easier for people who smoke to access them, will help ensure more people can be smoke-free, reducing the risk of illness and premature death.”
Smoking remains a leading public health challenge in the UK, contributing to around 80,000 deaths annually and imposing a £21.8 billion economic burden.(2) Tobacco is the most preventable cause of ill health and death in the UK and, if further action is not taken, nearly half a million more people may die from smoking by 2030.(2),(3)
“Smoking is the leading cause of premature, preventable death in the UK,” said Dr Gillian Lowrey, Respiratory Consultant at University Hospitals of Derby and Burton. “Cytisine gives healthcare professionals an additional stop smoking option to prescribe to patients, particularly those who want to avoid continued nicotine use. Many people prefer oral medications for convenience and Cytisine give them options.”
Those wishing to quit smoking are encouraged to visit their local stop smoking services or speak with a healthcare professional to discuss treatment options.
UK-CYT-226
Date of Preparation: January 2025
Notes to Editors:
- NICE Guidance NG209: https://www.nice.org.uk/guidance/ng209
- Spokespersons are available for interview on request
Got a Questions?
Find us on Socials or Contact us and we’ll get back to you as soon as possible.